KEGG   DISEASE: Parathyroid carcinomaHelp
Entry
H01558                      Disease                                

Name
Parathyroid carcinoma
Description
Parathyroid carcinoma (PC) is a highly aggressive endocrine tumor, with an annual incidence of less than 1 per million. Over 90% of patients present with excess parathyroid hormone (PTH), representing <1-5% of all patients with primary hyperparathyroidism. PC is associated with mutations in the HRPT2/CDC73 gene and with decreased parafibromin and calcium-sensing receptor (CASR) expression. Negative parafibromin staining together with a CDC73 gene mutation increases the likelihood of malignancy and also predicts the clinical outcome, namely local invasion and/or metastases and mortality. An increased mortality is predicted by either of these abnormality combined with down regulation of the calcium-sensing receptor (CaSR) expression.
Category
Cancer
Brite
Human diseases [BR:br08402]
 Cancers
  Cancers of endocrine organs
   H01558  Parathyroid carcinoma
Human diseases in ICD-11 classification [BR:br08403]
 02 Neoplasms
  In situ neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues
   2E6B  Carcinoma in situ of thyroid and other endocrine glands
    H01558  Parathyroid carcinoma
BRITE hierarchy
Gene
CDC73/HRPT2 (mutation) [HSA:79577] [KO:K15175]
CASR [HSA:846] [KO:K04612]
Drug
Cinacalcet hydrochloride [DR:D03505]
Other DBs
ICD-11: 2E6B
ICD-10: D09.3
MeSH: D010282
Reference
PMID:26177319 (description, gene, marker)
  Authors
Duan K, Mete O
  Title
Parathyroid Carcinoma: Diagnosis and Clinical Implications.
  Journal
Turk Patoloji Derg 31 Suppl 1:80-97 (2015)
DOI:10.5146/tjpath.2015.01316
Reference
PMID:26312219 (drug)
  Authors
McClenaghan F, Qureshi YA
  Title
Parathyroid cancer.
  Journal
Gland Surg 4:329-38 (2015)
DOI:10.3978/j.issn.2227-684X.2015.05.09
Reference
  Authors
Costa-Guda J, Arnold A
  Title
Genetic and epigenetic changes in sporadic endocrine tumors: parathyroid tumors.
  Journal
Mol Cell Endocrinol 386:46-54 (2014)
DOI:10.1016/j.mce.2013.09.005
Reference
  Authors
Givi B, Shah JP
  Title
Parathyroid carcinoma.
  Journal
Clin Oncol (R Coll Radiol) 22:498-507 (2010)
DOI:10.1016/j.clon.2010.04.007
Reference
PMID:25002250 (marker)
  Authors
Truran PP, Johnson SJ, Bliss RD, Lennard TW, Aspinall SR
  Title
Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.
  Journal
World J Surg 38:2845-54 (2014)
DOI:10.1007/s00268-014-2700-2
Reference
PMID:26675091 (marker)
  Authors
Karaarslan S, Yurum FN, Kumbaraci BS, Pala EE, Sivrikoz ON, Akyildiz M, Bugdayci MH
  Title
The Role of Parafibromin, Galectin-3, HBME-1, and Ki-67 in the Differential Diagnosis of Parathyroid Tumors.
  Journal
Oman Med J 30:421-7 (2015)
DOI:10.5001/omj.2015.84
Reference
  Authors
Cetani F, Pardi E, Marcocci C
  Title
Update on parathyroid carcinoma.
  Journal
J Endocrinol Invest 39:595-606 (2016)
DOI:10.1007/s40618-016-0447-3
Reference
  Authors
Witteveen JE, Hamdy NA, Dekkers OM, Kievit J, van Wezel T, Teh BT, Romijn JA, Morreau H
  Title
Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.
  Journal
Mod Pathol 24:688-97 (2011)
DOI:10.1038/modpathol.2010.236

» Japanese version

DBGET integrated database retrieval system